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Introduction: Liver transplantation currently represents the only curative treatment for Wilson’s disease. A lifelong
immunosuppressive therapy is mandatory. In spite of increased maternal and fetal risks, pregnancies after liver
transplantation have been reported with favorable perinatal outcomes. Hypoplastic left heart syndrome is a
spectrum of congenital heart defects that results in the inability to support the systemic circulation. Although its
etiology remains elusive, the prognosis of this previously fatal condition has dramatically improved over the last 2
decades mainly due to advances in prenatal diagnosis, surgical technique and perioperative care.
Case presentation: We present a case of a Caucasian 26-year-old woman, gravida 2, para 1 at 36+0 weeks of
gestation who had received a liver transplantation due to Wilson’s disease and subsequently delivered a child
with hypoplastic left heart syndrome.
Conclusions: This coincidence of medical conditions has not been described in the literature so far and its
implications for mother and child as well as the pathophysiological mechanisms are discussed on the basis of a
literature review.
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Several acquired, inherited or autoimmune hepatic dis-
orders can necessitate liver transplantation. Wilson’s
disease is a rare autosomal recessive disorder of copper
metabolism that can lead to hepatic failure and neuro-
logical degeneration. The underlying mechanism is a
mutation of the copper-transporting adenosine tripho-
sphatase gene (ATP7B) located on the long arm of
chromosome 13. The worldwide prevalence is 1 in
30,000. Clinical manifestation due to copper accumula-
tion is highly variable, ranging from mild hepatitis to
acute liver failure and cirrhosis. Liver transplantation
with lifelong immunosuppressive therapy represents the
only curative treatment [1].* Correspondence: Antonia.wenners@uksh.de
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stated.Hypoplastic left heart syndrome (HLHS) is a congeni-
tal heart defect characterized by variable hypoplasia of
the left ventricle, stenosis or atresia of mitral and/or aor-
tic valves and aortic arch hypoplasia, resulting in the in-
ability of the left side of the heart to support the
systemic circulation. This cardiac malformation occurs
in about 0.02% of all live births. The etiology of HLHS is
not yet fully understood but a multifactorial pathogen-
esis can be assumed. Risk factors might include familial,
infectious, maternal and gestational conditions. A gen-
etic influence seems probable although no specific gene
has been identified so far. Whether maternal immuno-
suppression during pregnancy can cause HLHS is un-
known [2,3].
The first pregnancy in a liver transplant recipient was
reported by Walcott et al. in 1978 [4]. Since then,
hundreds of pregnancies after orthotopic liver trans-
plantation have been reported with favorable perinatalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Prenatal fetal echocardiography showing a four chamber view of the fetus affected with hypoplastic left heart syndrome.
Abbreviations: LA, Left atrium; LV, Left ventricle; RA, Right atrium; RV, Right ventricle.
Figure 2 Postnatal transthoracal echocardiography (four chamber view): severe hypoplasia of the left ventricle with endocardial
fibroelastosis and hypoplasia of the left atrium are seen. Abbreviations: LA, Left atrium; LV, Left ventricle; RA, Right atrium; RV, Right ventricle.
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liver transplantation in adolescence due to Wilson’s dis-
ease and discuss the potential chain of cause and effect.
Case presentation
A Caucasian 26-year-old woman, gravida 2, para 1 at
36+0 weeks of gestation was admitted to our hospital
with fetal HLHS and contractions, not affecting her cer-
vix. She had received a liver transplant at 16 years of age
because of acute liver failure due to Wilson’s disease.
Her immunosuppression was maintained with tacroli-
mus. Her first pregnancy at the age of 21 years had been
uneventful.
In the second pregnancy a prenatal ultrasound scan at
18 weeks’ gestation revealed fetal HLHS (Figure 1). The
fetus’s left ventricle and ascending aorta were hypoplas-
tic (1.5 mm aortal width) and were perfused retrogradely
via the ductus arteriosus. The fetus’s right ventricular
function was adequate. In the medical history of the pa-
tient, no cardiac disease was known in the concerned
families. The further pregnancy course was uneventful
with normal maternal liver and renal function under
immunosuppression with tacrolimus. The fetal growth,
Doppler analysis and amniotic fluid were in normal
ranges. No signs of preeclampsia, infection or transplant
rejection were apparent.
Primary re-cesarean section was performed at 37+0
weeks of gestational age. A male neonate weighing
3380 g was delivered, his APGAR scores (the criteria
are appearance, pulse, grimace, activity and respiration)
were 8, 9 and 10, pH was 7.24 and base excess −2.8.
The newborn was set on prostaglandin infusion ther-
apy. Postnatal echocardiography confirmed the diagnosis
of HLHS with mitral and aortic valve atresia as well
as hypoplasia of his left ventricle and ascending aorta
(Figure 2). Other medication given to the newbornTable 1 Immunosuppressants and their side effects in pregna
Drug Metabolism
In the mother
Corticosteroids IL-2 synthesis inhibition Hypertension Gestational diabe
Osteonecrosis Cataracts Striae
Cyclosporine Inhibition of cytokine
production
Hypertension Gestational diabe
Renal dysfunction Uterine dyst
Seizures
Azathioprine Antimetabolic: inhibition
















Abbreviations: esp. especially, IL Interleukin, IUGR Intrauterine growth retardation, PRincluded intravenous furosemide and afterload reduction
with sodium nitroprusside. A Norwood operation with a
3.5 mm Blalock–Taussig shunt was performed 3 days
after delivery without complications. In the following
weeks, digoxin and furosemide therapy was instituted
orally to reduce symptoms of mild heart failure related
to pulmonary over-circulation. He was on full oral feed-
ings and was discharged from the hospital with a home
monitoring protocol at the age of 6 weeks.
After delivery the mother was in perfect health, no re-
jection episode was observed and discharge was possible
after 5 days. Immunosuppressive therapy was continued
postnatally with tacrolimus adapted to serum blood
levels.
Discussion
We describe a case of HLHS after maternal liver trans-
plantation due to Wilson’s disease. The most important
risks for the fetus in mothers with a liver transplant are
preterm delivery (31%) and low birth weight (23%). At-
tributed maternal risks are pregnancy-induced hyperten-
sion, preeclampsia and infection during pregnancy [5].
In patients who have had liver transplantation no sig-
nificantly higher incidence of malformation patterns has
been shown [5]. Abortions occur more often in trans-
plant recipients whose underlying disease was auto-
immune cirrhosis than in recipients with inherited
disorders such as Wilson’s disease [5]. Wilson’s disease
has not been associated with an increased risk for other
genetic disorders.
Dei Malatesta et al. found that higher rates of both
abortions (19%) and pregnancy complications in a trans-
plantation collective were inversely related to the time
interval between transplantation and conception [5].
While the timing of pregnancy is controversially dis-
cussed, current recommendations are to wait for at leastnt liver transplant recipients
Side effects References
In the fetus
tes Malformation (4%, esp. cleft palate) Low birth




Malformation (3–5%; no consistent pattern known)
Low birth weight Jaundice Cytopenia
Hypoglycemia Intracerebral hemorrhage
[6,13,14]
Malformation (7%; esp. aphallia, hypo- or dysplasia
of lungs and urinary bladder) IUGR Premature




Malformation (6%; no consistent pattern known)
Transient increase of potassium Impaired renal
function
[6,17-19]
Malformation (22%; esp. cleft lip and palate,
micrognathia, ear malformations) 1st trimester
fetal loss Anemia
[6,20,21]
OM Premature rupture of membranes.
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the incidence of malformations is not higher in new-
borns after maternal liver transplantation compared to
the general population, malformation patterns including
severe heart defects could potentially account for the
higher abortion rates [7].
The etiology of HLHS remains unknown but may
include chromosomal, genetic, infectious, immunosup-
pressive, teratogenic conditions and other factors [3].
Although a genetic involvement is strongly suspected,
no single gene has been identified to cause HLHS.
Chromosomal anomalies occur in up to 5 to 12% of chil-
dren with HLHS and an association with Turner’s syn-
drome as well as trisomy 18 and 13 has been described.
The genetic alteration most commonly associated with
HLHS is the terminal 11q deletion (Jacobsen’s syn-
drome) in which the incidence of HLHS is 10% [8]. The
recurrence risk of HLHS is estimated to be 2 to 4%
when a previous newborn was affected [8,9]. ATP7B is
the gene product of the Wilson’s disease gene and is
located on chromosome 13. More than 300 different
mutations have been identified to date [10]. In Europe
the most common mutation is the point mutation
H1069Q in exon 14, which underlies 30 to 60% of all
mutations in Caucasians [11]. A direct linkage between
this gene defect in the mother and HLHS in the child
seems to be not possible.
Increased rates of infection during pregnancy (20%)
are known to occur in patients after liver transplantation
compared to the general population. The higher inci-
dence of infection during pregnancy in patients who
have had liver transplantation is most probably related
to immunosuppressant therapy. Table 1 shows that dif-
ferent immunosuppressants have a variable impact on
the pregnancy course and outcome. Fetal exposure to
active maternal infections including Cytomegalovirus
(CMV) infection presents an increased risk for HLHS
[3]. In our case, however, no infection was diagnosed
during pregnancy; repeated testing for CMV was
negative.
Teratogenic agents can cause anatomical defects in the
child, for example valproic acid. In terms of immuno-
suppression due to post-transplant prevention of graft
rejection, potential benefits may outweigh these risks
(Table 1). A person can also be immunosuppressed for a
broad spectrum of other reasons, for example severe
combined immunodeficiency or human immunodefi-
ciency virus and rheumatic diseases. So far, no direct
association between immunosuppressive treatment after
liver transplantation and fetal heart malformation has
been established. In particular, there is no evidence of
an increased rate of fetal HLHS in immunosuppressed
mothers. Although for tacrolimus the malformation
rate is estimated to be 6%, several studies and reportsconfirm the safety of tacrolimus during pregnancy after
transplantation [17-19].
Not a single case of HLHS has been described in con-
nection with immunosuppression until now. We there-
fore feel that the likelihood of a causal relationship
between tacrolimus therapy of the mother during preg-
nancy and HLHS in the fetus is low, in particular be-
cause the mother had delivered a healthy older child and
had no history of abortions.
Conclusions
In summary, liver transplantation affects pregnancy and
fetal outcome, but an association with severe congenital
heart defects or other malformations in newborns has
not been established. However, it has to be considered
that data may be limited due to underreporting or a
small number of cases. The present case of the combin-
ation of fetal HLHS and maternal liver transplantation
due to Wilson’s disease is probably coincidental, as there
is little evidence in the literature for an underlying
causal mechanism.
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